BioSpace News Archive

Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced upcoming presentations at the Innovation in Cardiovascular Interventions (ICI) Meeting in Tel-Aviv, Israel

Mary Jean Tully, Founder and CEO of Tully Luxury Travel (TLT) was honored to celebrate the third year of a five-year commitment she has made on behalf of TLT to CANFAR’s Bloor Street Entertains on November 27th.

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has directly entered into an agreement for the sale of its common stock in a private placement with a group of institutional investors.

Samus Therapeutics, Inc. (“Samus” or the “Company”), a privately held, Boston-based, biopharmaceutical company developing epichaperome inhibitors to intervene in pathological processes and initiate the degradation of disease-associated proteins, today announced the presentation of initial Phase 1 data for Alzheimer’s Disease at the 12th annual Clinical Trials in Alzheimer’s Disease (CTAD) Congress,

Epic Sciences, Inc. today announced the presentation of new data demonstrating the feasibility of using its proprietary technology for the detection and characterization of rare cells to guide the treatment of breast cance

Program Pairs GYN Patients with Trained Advocates Who Assist with Clinical, Emotional and Financial Aspects of Surgical Care

Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application to proceed with a U.S. clinical trial of MV-012-968, an investigational vaccine for respiratory syncytial virus (RSV).

Akoya Biosciences, Inc., The Spatial Biology Company™, today announced the completion of a $50 million financing from both new and existing investors.

Technavio has announced its latest market research report titled global esophageal cancer drugs market 2019-2023

Making the M-60 the Most Versatile Extraction Press in the Industry